[
    [
        {
            "time": "2018-01-03",
            "original_text": "Wednesday's ETF with Unusual Volume: PPH",
            "features": {
                "keywords": [
                    "ETF",
                    "unusual volume",
                    "PPH"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "finance"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Wednesday's ETF with Unusual Volume: PPH",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 3,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-01-04",
            "original_text": "Add These 7 GARP Stocks to Your Portfolio for Better Returns",
            "features": {
                "keywords": [
                    "GARP stocks",
                    "portfolio",
                    "better returns"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "general"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Add These 7 GARP Stocks to Your Portfolio for Better Returns",
                "Correlation": 4,
                "Sentiment": 7,
                "Importance": 5,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 2,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-01-05",
            "original_text": "Humira Will Remain a Key Growth Driver for AbbVie in 2018",
            "features": {
                "keywords": [
                    "Humira",
                    "growth driver",
                    "AbbVie"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Humira Will Remain a Key Growth Driver for AbbVie in 2018",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 7,
                "Market_Scope": 3,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-01-06",
            "original_text": "Gilead (GILD) Beats on Q4 Earnings, 2018 View Lacks Lustre",
            "features": {
                "keywords": [
                    "Gilead",
                    "Q4 earnings",
                    "2018 view"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "biotechnology"
                ],
                "causal_factor": "true",
                "causal_impact": "mixed",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Gilead (GILD) Beats on Q4 Earnings, 2018 View Lacks Lustre",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-01-07",
            "original_text": "Why AbbVie Inc.'s Shares Rocketed 16% in January",
            "features": {
                "keywords": [
                    "AbbVie",
                    "shares rocketed",
                    "January"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Why AbbVie Inc.'s Shares Rocketed 16% in January",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 9,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-01-08",
            "original_text": "AbbVie Expected to Witness Strong Growth in Margins in 2018",
            "features": {
                "keywords": [
                    "AbbVie",
                    "strong growth",
                    "margins"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "AbbVie Expected to Witness Strong Growth in Margins in 2018",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-01-09",
            "original_text": "Gilead Sciences Inc. Delivers Deja Vu in the Fourth Quarter",
            "features": {
                "keywords": [
                    "Gilead Sciences",
                    "deja vu",
                    "fourth quarter"
                ],
                "sentiment_score": 0.4,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "biotechnology"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Gilead Sciences Inc. Delivers Deja Vu in the Fourth Quarter",
                "Correlation": 9,
                "Sentiment": 4,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-01-10",
            "original_text": "Why AbbVie is a Top 25 Dividend Giant (ABBV)",
            "features": {
                "keywords": [
                    "AbbVie",
                    "dividend giant"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Why AbbVie is a Top 25 Dividend Giant (ABBV)",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-01-11",
            "original_text": "Why AbbVie Inc.'s Shares Rocketed 16% in January",
            "features": {
                "keywords": [
                    "AbbVie",
                    "shares rocketed",
                    "January"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Why AbbVie Inc.'s Shares Rocketed 16% in January",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 9,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-01-12",
            "original_text": "Tax Cuts and Jobs Act Has Proven a Major Boon for AbbVie in 2018",
            "features": {
                "keywords": [
                    "tax cuts",
                    "jobs act",
                    "boon",
                    "AbbVie"
                ],
                "sentiment_score": 0.9,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Tax Cuts and Jobs Act Has Proven a Major Boon for AbbVie in 2018",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-01-13",
            "original_text": "New Research: Key Drivers of Growth for Rockwell Automation, Voya Financial, EPR Properties, Hudson Pacific Properties, AbbVie, and Ventas — Factors of Influence, Major Initiatives and Sustained Production",
            "features": {
                "keywords": [
                    "key drivers",
                    "growth",
                    "Rockwell Automation",
                    "Voya Financial",
                    "EPR Properties",
                    "Hudson Pacific Properties",
                    "AbbVie",
                    "Ventas"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "industrial",
                    "financial services",
                    "real estate",
                    "pharmaceuticals",
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "New Research: Key Drivers of Growth for Rockwell Automation, Voya Financial, EPR Properties, Hudson Pacific Properties, AbbVie, and Ventas — Factors of Influence, Major Initiatives and Sustained Production",
                "Correlation": 7,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 6,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        }
    ]
]